23andMe board resigns

The entire board of directors of 23andMe, a leading consumer genetics company, has resigned. The board's departure comes after months of disagreement with CEO Anne Wojcicki over her plans to take the company private.
In a letter to Wojcicki, the board members wrote that they had "lost confidence" in her ability to lead the company. They cited her "lack of transparency" and "unwillingness to consider alternative proposals" as reasons for their decision.
Wojcicki, who is also a co-founder of 23andMe, said she was "surprised and disappointed" by the board's decision. She said she believes that her plan to take the company private is in the best interests of shareholders and employees.
The board's resignation is a major setback for 23andMe. The company has been struggling financially in recent months, and its stock price has fallen sharply. The board's departure could make it even more difficult for the company to regain its footing.
The news of the board's resignation sent 23andMe's stock price down by more than 10% in after-hours trading. The stock has now lost more than half of its value since Wojcicki announced her plans to take the company private in March.
It is unclear what the future holds for 23andMe. The company could continue to operate with a new board of directors, or it could be sold to another company. It is also possible that the company could file for bankruptcy.
The board's resignation is a reminder of the challenges facing many companies in the rapidly changing healthcare industry. As technology advances, companies must adapt or risk being left behind. 23andMe is a case in point. The company was once a leader in the field of consumer genetics, but it has struggled to keep up with the competition.
The board's resignation is a major setback for 23andMe, but it is not the end of the company. The company has a strong brand and a loyal customer base. If it can find a way to address its financial challenges, it could still have a bright future.